TY  - JOUR
AU  - Stanisavljević, Nataša
AU  - Stojanovich, Ljudmila
AU  - Đoković, Aleksandra
AU  - Todić, Brankica
AU  - Dopsaj, Violeta
AU  - Saponjski, Jovica
AU  - Saponjski, Dušan
AU  - Marković, Olivera
AU  - Belizna, Cristina
AU  - Zdravković, Marija
AU  - Marisavljević, Dragomir
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4310
AB  - Objective: The potential contribution of asymmetric dimethylarginine (ADMA) and high-sensitivity C reactive protein (hsCRP) to endothelial dysfunction in APS patients has not been studied in detail, until now. The study involved 105 APS patients (59 diagnosed with primary APS (PAPS) and 46 APS associated with systemic lupus erythematosus (SAPS)) who were compared to 40 controls. Endothelial dysfunction was assessed by measurement of flow-mediated dilatation (FMD) and glyceryl trinitrate dilatation (NMD) of the brachial artery. ADMA (micromol/L) was analyzed by ELISA. Results: FMD in patients with APS was significantly lower than that of the controls (p < 0.001), with no difference between the PAPS and the SAPS groups. ADMA and hsCRP concentrations were significantly higher in the patient cohort than in the control group (p < 0.001, p = 0.006, respectively), as was the case with the SAPS group as compared to the PAPS group (p < 0.001, p = 0.022, respectively). FMD impairment correlated to ADMA (ρ 0.472, p < 0.001) and to hsCRP (ρ 0.181, p = 0.033). In the regression model, the ADMA concentration confirmed the strength of its association (B 0.518, SE 0.183, Wald 8.041, p = 0.005, Exp(B) 1.679, 95% CI 1.174–2.402) to FMD impairment. The synergistic probability model of ADMA and hsCRP caused FMD impairment when the positivity of β2GPIIgG was added. ADMA may be used as a simple and low-cost tool for verifying the presence of endothelial dysfunction in APS patients. According to the results of the study, we could presume that hsCRP, together with aPL, has a preparatory effect on the endothelium in causing endothelial dysfunction.
PB  - MDPI
T2  - International Journal of Molecular Sciences
T1  - Asymmetric Dimethylarginine Is a Marker of Endothelial Dysfunction in Thrombotic Antiphospholipid Syndrome Patients
VL  - 23
IS  - 20
DO  - 10.3390/ijms232012309
ER  - 

@article{
author = "Stanisavljević, Nataša and Stojanovich, Ljudmila and Đoković, Aleksandra and Todić, Brankica and Dopsaj, Violeta and Saponjski, Jovica and Saponjski, Dušan and Marković, Olivera and Belizna, Cristina and Zdravković, Marija and Marisavljević, Dragomir",
year = "2022",
abstract = "Objective: The potential contribution of asymmetric dimethylarginine (ADMA) and high-sensitivity C reactive protein (hsCRP) to endothelial dysfunction in APS patients has not been studied in detail, until now. The study involved 105 APS patients (59 diagnosed with primary APS (PAPS) and 46 APS associated with systemic lupus erythematosus (SAPS)) who were compared to 40 controls. Endothelial dysfunction was assessed by measurement of flow-mediated dilatation (FMD) and glyceryl trinitrate dilatation (NMD) of the brachial artery. ADMA (micromol/L) was analyzed by ELISA. Results: FMD in patients with APS was significantly lower than that of the controls (p < 0.001), with no difference between the PAPS and the SAPS groups. ADMA and hsCRP concentrations were significantly higher in the patient cohort than in the control group (p < 0.001, p = 0.006, respectively), as was the case with the SAPS group as compared to the PAPS group (p < 0.001, p = 0.022, respectively). FMD impairment correlated to ADMA (ρ 0.472, p < 0.001) and to hsCRP (ρ 0.181, p = 0.033). In the regression model, the ADMA concentration confirmed the strength of its association (B 0.518, SE 0.183, Wald 8.041, p = 0.005, Exp(B) 1.679, 95% CI 1.174–2.402) to FMD impairment. The synergistic probability model of ADMA and hsCRP caused FMD impairment when the positivity of β2GPIIgG was added. ADMA may be used as a simple and low-cost tool for verifying the presence of endothelial dysfunction in APS patients. According to the results of the study, we could presume that hsCRP, together with aPL, has a preparatory effect on the endothelium in causing endothelial dysfunction.",
publisher = "MDPI",
journal = "International Journal of Molecular Sciences",
title = "Asymmetric Dimethylarginine Is a Marker of Endothelial Dysfunction in Thrombotic Antiphospholipid Syndrome Patients",
volume = "23",
number = "20",
doi = "10.3390/ijms232012309"
}

Stanisavljević, N., Stojanovich, L., Đoković, A., Todić, B., Dopsaj, V., Saponjski, J., Saponjski, D., Marković, O., Belizna, C., Zdravković, M.,& Marisavljević, D.. (2022). Asymmetric Dimethylarginine Is a Marker of Endothelial Dysfunction in Thrombotic Antiphospholipid Syndrome Patients. in International Journal of Molecular Sciences
MDPI., 23(20).
https://doi.org/10.3390/ijms232012309

Stanisavljević N, Stojanovich L, Đoković A, Todić B, Dopsaj V, Saponjski J, Saponjski D, Marković O, Belizna C, Zdravković M, Marisavljević D. Asymmetric Dimethylarginine Is a Marker of Endothelial Dysfunction in Thrombotic Antiphospholipid Syndrome Patients. in International Journal of Molecular Sciences. 2022;23(20).
doi:10.3390/ijms232012309 .

Stanisavljević, Nataša, Stojanovich, Ljudmila, Đoković, Aleksandra, Todić, Brankica, Dopsaj, Violeta, Saponjski, Jovica, Saponjski, Dušan, Marković, Olivera, Belizna, Cristina, Zdravković, Marija, Marisavljević, Dragomir, "Asymmetric Dimethylarginine Is a Marker of Endothelial Dysfunction in Thrombotic Antiphospholipid Syndrome Patients" in International Journal of Molecular Sciences, 23, no. 20 (2022),
https://doi.org/10.3390/ijms232012309 . .

TY  - CONF
AU  - Stojanović, Ljudmila
AU  - Stanisavljević, Nataša
AU  - Marisavljević, D.
AU  - Dopsaj, Violeta
AU  - Todić, B.
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2648
PB  - BMJ PUBLISHING GROUP, LONDON
C3  - Annals of the Rheumatic Diseases
T1  - The oxidative stress markers as risk factor for endothelial dysfunction in primary and secondary antiphospholipid syndrome
VL  - 75
IS  - Supplement 2
SP  - 284
EP  - 284
DO  - 10.1136/annrheumdis-2016-eular.1782
ER  - 

@conference{
author = "Stojanović, Ljudmila and Stanisavljević, Nataša and Marisavljević, D. and Dopsaj, Violeta and Todić, B.",
year = "2016",
publisher = "BMJ PUBLISHING GROUP, LONDON",
journal = "Annals of the Rheumatic Diseases",
title = "The oxidative stress markers as risk factor for endothelial dysfunction in primary and secondary antiphospholipid syndrome",
volume = "75",
number = "Supplement 2",
pages = "284-284",
doi = "10.1136/annrheumdis-2016-eular.1782"
}

Stojanović, L., Stanisavljević, N., Marisavljević, D., Dopsaj, V.,& Todić, B.. (2016). The oxidative stress markers as risk factor for endothelial dysfunction in primary and secondary antiphospholipid syndrome. in Annals of the Rheumatic Diseases
BMJ PUBLISHING GROUP, LONDON., 75(Supplement 2), 284-284.
https://doi.org/10.1136/annrheumdis-2016-eular.1782

Stojanović L, Stanisavljević N, Marisavljević D, Dopsaj V, Todić B. The oxidative stress markers as risk factor for endothelial dysfunction in primary and secondary antiphospholipid syndrome. in Annals of the Rheumatic Diseases. 2016;75(Supplement 2):284-284.
doi:10.1136/annrheumdis-2016-eular.1782 .

Stojanović, Ljudmila, Stanisavljević, Nataša, Marisavljević, D., Dopsaj, Violeta, Todić, B., "The oxidative stress markers as risk factor for endothelial dysfunction in primary and secondary antiphospholipid syndrome" in Annals of the Rheumatic Diseases, 75, no. Supplement 2 (2016):284-284,
https://doi.org/10.1136/annrheumdis-2016-eular.1782 . .

TY  - JOUR
AU  - Becarević, Mirjana
AU  - Stojanović, Ljudmila
AU  - Ignjatović, Svetlana
AU  - Dopsaj, Violeta
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2590
AB  - We evaluated the importance of anti-annexin A5 antibodies (aanxA5 Abs) for clinical (thrombosis and/or recurrent pregnancy loss) and serologic (presence of antiphospholipid antibodies: lupus anticoagulant (LA), anticardiolipin (aCL), and anti-beta 2 glycoprotein I (a beta 2GPI) antibodies) features of patients with primary antiphospholipid syndrome (PAPS). Our study included 70 patients with PAPS according to the international consensus criteria for APS. The mean age of the analyzed patients was 45.97 +/- 12.72. The disease duration above 5 years was present in 31/70 of patients. Concentrations of analyzed antibodies were measured by ELISA. Cutoff values were set in accordance to the manufacturers' recommendations. History of recurrent pregnancy loss was associated with double positivity for aanxA5 IgM and LA (chi (2) = 4.000, P = 0.046) and triple positivity for aanxA5 IgM + LA + a beta 2GPI IgM (chi (2) = 4.168, P = 0.041). Venous thromboses were associated with triple positivity for aanxA5 IgM + aCLIgG + a beta 2GPI IgM (chi (2) = 3.965, P = 0.046). The IgG isotype of aanxA5 Abs was in positive correlation with aCL Abs of the IgG (r = 0.310, P = 0.009) and IgM (r = 0.254, P = 0.034) isotype. The presence of the clinical manifestations of PAPS is increasing with the number of positive conventional aPL and the IgM aanxA5 Abs tests. This new combination of Abs is beneficial even when the number of patients with positivity for aanxA5 Abs is low. This is important in further detection of patients prone to recurrence of thrombotic episodes.
PB  - Springer London Ltd, London
T2  - Clinical Rheumatology
T1  - The IgM isotype of anti-annexin A5 antibodies and multiple positivity of conventional antiphospholipid antibodies: increasing the number of clinical manifestations of primary antiphospholipid syndrome
VL  - 35
IS  - 5
SP  - 1361
EP  - 1365
DO  - 10.1007/s10067-016-3230-0
ER  - 

@article{
author = "Becarević, Mirjana and Stojanović, Ljudmila and Ignjatović, Svetlana and Dopsaj, Violeta",
year = "2016",
abstract = "We evaluated the importance of anti-annexin A5 antibodies (aanxA5 Abs) for clinical (thrombosis and/or recurrent pregnancy loss) and serologic (presence of antiphospholipid antibodies: lupus anticoagulant (LA), anticardiolipin (aCL), and anti-beta 2 glycoprotein I (a beta 2GPI) antibodies) features of patients with primary antiphospholipid syndrome (PAPS). Our study included 70 patients with PAPS according to the international consensus criteria for APS. The mean age of the analyzed patients was 45.97 +/- 12.72. The disease duration above 5 years was present in 31/70 of patients. Concentrations of analyzed antibodies were measured by ELISA. Cutoff values were set in accordance to the manufacturers' recommendations. History of recurrent pregnancy loss was associated with double positivity for aanxA5 IgM and LA (chi (2) = 4.000, P = 0.046) and triple positivity for aanxA5 IgM + LA + a beta 2GPI IgM (chi (2) = 4.168, P = 0.041). Venous thromboses were associated with triple positivity for aanxA5 IgM + aCLIgG + a beta 2GPI IgM (chi (2) = 3.965, P = 0.046). The IgG isotype of aanxA5 Abs was in positive correlation with aCL Abs of the IgG (r = 0.310, P = 0.009) and IgM (r = 0.254, P = 0.034) isotype. The presence of the clinical manifestations of PAPS is increasing with the number of positive conventional aPL and the IgM aanxA5 Abs tests. This new combination of Abs is beneficial even when the number of patients with positivity for aanxA5 Abs is low. This is important in further detection of patients prone to recurrence of thrombotic episodes.",
publisher = "Springer London Ltd, London",
journal = "Clinical Rheumatology",
title = "The IgM isotype of anti-annexin A5 antibodies and multiple positivity of conventional antiphospholipid antibodies: increasing the number of clinical manifestations of primary antiphospholipid syndrome",
volume = "35",
number = "5",
pages = "1361-1365",
doi = "10.1007/s10067-016-3230-0"
}

Becarević, M., Stojanović, L., Ignjatović, S.,& Dopsaj, V.. (2016). The IgM isotype of anti-annexin A5 antibodies and multiple positivity of conventional antiphospholipid antibodies: increasing the number of clinical manifestations of primary antiphospholipid syndrome. in Clinical Rheumatology
Springer London Ltd, London., 35(5), 1361-1365.
https://doi.org/10.1007/s10067-016-3230-0

Becarević M, Stojanović L, Ignjatović S, Dopsaj V. The IgM isotype of anti-annexin A5 antibodies and multiple positivity of conventional antiphospholipid antibodies: increasing the number of clinical manifestations of primary antiphospholipid syndrome. in Clinical Rheumatology. 2016;35(5):1361-1365.
doi:10.1007/s10067-016-3230-0 .

Becarević, Mirjana, Stojanović, Ljudmila, Ignjatović, Svetlana, Dopsaj, Violeta, "The IgM isotype of anti-annexin A5 antibodies and multiple positivity of conventional antiphospholipid antibodies: increasing the number of clinical manifestations of primary antiphospholipid syndrome" in Clinical Rheumatology, 35, no. 5 (2016):1361-1365,
https://doi.org/10.1007/s10067-016-3230-0 . .